BACKGROUND Chronic lymphocytic leukemia has a variable clinical course. Genomic aberrations identify prognostic subgroups, pointing towards distinct underlying biological mechanisms that are poorly understood. In particular it remains unclear whether the prognostic subgroups of chronic lymphocytic leukemia are characterized by different levels of leukemogenic proteins. DESIGN AND METHODS Expr...

We report the case of a 48-year-old man who achieved a complete molecular remission 20 years after a diagnosis of chronic lymphocytic leukemia while using epigallicatechin-3-gallate, an extract of green tea. The patient presented at age 28 with lymphocytosis, mild anemia, mild thrombocytopenia, and massive splenomegaly, for which a splenectomy was performed. He was then followed expectantly. Ov...

Chronic lymphocytic leukemia is marked by profound defects in T-cell function. Programmed death-1 is a receptor involved in tumor-mediated immunosuppression through binding of the PD-L1 ligand. Multiparametric flow cytometry and immunohistochemistry were used to study PD-1/PD-L1 expression. Functional assays were used to determine the involvement of the PD-1/PD-L1 axis in T-cell responses. PD-1...

BACKGROUND In chronic lymphocytic leukemia lenalidomide causes striking immune activation, possibly leading to clearance of tumor cells. We conducted this study to investigate the mechanism of action of lenalidomide and the basis for its unique toxicities in chronic lymphocytic leukemia. DESIGN AND METHODS Patients with relapsed chronic lymphocytic leukemia were treated with lenalidomide 20 m...

Nonhuman primate antisera defining leukemia-associ ated and normal Tand B-lymphocyte-associated anti gens were used to characterize serologically the cells from acute myelomonocytic leukemia (AMML) and chronic myelogenous leukemia patients in blast crisis (CML-BC). Earlier studies demonstrated that nonhuman primate an tisera to chronic lymphocytic leukemia, acute myelogen ous leukemia, and chro...

Cryptococcus neoformans is an encapsulated yeast that typically causes illness in immunocompromised hosts. Manifestations of the disease include pulmonary, Central Nervous System (CNS), and rare skeletal involvement. Optimal antifungal therapy for involvement has yet to be established. Here we present a potential regimen disseminated cryptococcal with pulmonary patient Chronic Lymphocytic Leuke...

The sialic acid content of erythrocytes from healthy individuals of different blood types and of patients with known hematological disorders has been determined. The sialic acid was completely released enzymatically with sialidase and quantitated by the thiobarbituric acid method. The sialic acid content of erythrocytes was constant irrespective of ABO blood type, or anticoagulant used; viz, 0....

Abbreviations: acute lymphoblastic leukemias, (ALLs); acute myeloid leukemia, (AML); arsenic trioxide, (ATO); B-cell chronic lymphocytic leukemia, (B-CLL); blast crisis, (BC); chronic lymphocytic leukemias, (CLL); CML-Acceleration Phase/Blast Crisis, (CML/AP/BC); CML-Bone Marrow Transplantation patients, (CML-BMT); CML-Chronic Phase patients, (CML/CP); DNA binding domain, (DBD); dominant-negati...

Bullous leukemia cutis is an uncommon clinical manifestation of cutaneous infiltration by leukemic cells, from B-cell chronic lymphocytic leukemia. We present the case of a 67-year-old, female, chronic lymphocytic leukemia patient. She was taking chlorambucil and developed facial edema with erythema and warmth, misjudged as facial cellulitis. Two days later, she developed bullous lesions in the...

Introduction: CLL is one of the most common leukemias, which is categorized by the accumulation of mature CD5+ B-lymphocytes in the peripheral blood, bone marrow, and secondary lymphoid organs. In this study, the status of rs6449182 polymorphism of the CD38 gene and its association with clinical and laboratory parameters of CLL patients was evaluated. Methods: Genomic DNA extraction was perfor...